BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27378194)

  • 1. Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning.
    Gadducci A; Biglia N; Tana R; Cosio S; Gallo M
    Crit Rev Oncol Hematol; 2016 Sep; 105():73-83. PubMed ID: 27378194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin: its emerging role in oncology.
    Micic D; Cvijovic G; Trajkovic V; Duntas LH; Polovina S
    Hormones (Athens); 2011; 10(1):5-15. PubMed ID: 21349801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C; Liu VW; Chan DW; Yao KM; Ngan HY
    Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy.
    Karadeniz Z; Aynacıoğlu AŞ; Bilir A; Tuna MY
    Med Hypotheses; 2020 Jan; 134():109420. PubMed ID: 31634770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer.
    Cai D; Sun H; Qi Y; Zhao X; Feng M; Wu X
    Int J Gynecol Cancer; 2016 Nov; 26(9):1667-1672. PubMed ID: 27654259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metformin--new treatment strategies for gynecologic neoplasms].
    Milewicz T; Kiałka M; Mrozińska S; Ociepka A; Krzysiek J
    Przegl Lek; 2013; 70(2):81-4. PubMed ID: 23879009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin and cancer.
    Vallianou NG; Evangelopoulos A; Kazazis C
    Rev Diabet Stud; 2013; 10(4):228-35. PubMed ID: 24841876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.
    Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X
    Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.
    Xie Y; Wang YL; Yu L; Hu Q; Ji L; Zhang Y; Liao QP
    J Steroid Biochem Mol Biol; 2011 Sep; 126(3-5):113-20. PubMed ID: 21168492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LKB1/AMPK inhibits TGF-β1 production and the TGF-β signaling pathway in breast cancer cells.
    Li NS; Zou JR; Lin H; Ke R; He XL; Xiao L; Huang D; Luo L; Lv N; Luo Z
    Tumour Biol; 2016 Jun; 37(6):8249-58. PubMed ID: 26718214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin: taking away the candy for cancer?
    Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
    Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
    Dowling RJ; Zakikhani M; Fantus IG; Pollak M; Sonenberg N
    Cancer Res; 2007 Nov; 67(22):10804-12. PubMed ID: 18006825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.
    Cai H; Zhang Y; Han TK; Everett RS; Thakker DR
    Int J Cancer; 2016 May; 138(9):2281-92. PubMed ID: 26669511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular targets of metformin antitumor action.
    Sośnicki S; Kapral M; Węglarz L
    Pharmacol Rep; 2016 Oct; 68(5):918-25. PubMed ID: 27362768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
    Wysocki PJ; Wierusz-Wysocka B
    Expert Rev Mol Diagn; 2010 May; 10(4):509-19. PubMed ID: 20465505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin in selected malignancies in women.
    Markowska A; Stanislawiak-Rudowicz J; Kasprzak T; Markowska J; Szarszewska M
    Ginekol Pol; 2022; 93(5):416-421. PubMed ID: 35072253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin and neoplasia: implications and indications.
    Aljada A; Mousa SA
    Pharmacol Ther; 2012 Jan; 133(1):108-15. PubMed ID: 21924289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
    Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
    Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.